The Keytruda Market segment is divided across multiple therapeutic areas, with oncology being the largest and most dominant. Within oncology, the drug is approved for various indications, including lung, melanoma, head and neck, bladder, and gastric cancers. Each therapeutic segment has its own growth trajectory depending on incidence rates, awareness, treatment guidelines, and...

The Keytruda Market segment is divided across multiple therapeutic areas, with oncology being the largest and most dominant. Within oncology, the drug is approved for various indications, including lung, melanoma, head and neck, bladder, and gastric cancers. Each therapeutic segment has its own growth trajectory depending on incidence rates, awareness, treatment guidelines, and...

Valued at USD 30.45 billion in 2025, the Keytruda market is projected to reach USD 33.26 billion in 2026 and USD 68.75 billion by 2034, growing at a CAGR of 9.5% during the forecast period 2026–2034. Leading companies include Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, AstraZeneca plc, Pfizer Inc., Novartis AG, Sanofi S.A., Johnson & Johnson, GSK plc,...